HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Joachim Stangier Selected Research

idarucizumab

1/2019Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
1/2017Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers.
1/2017Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
11/2016Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
11/2016Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
8/2015Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
8/2015Idarucizumab for Dabigatran Reversal.
7/2015Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Joachim Stangier Research Topics

Disease

11Hemorrhage
01/2019 - 11/2007
6Atrial Fibrillation
05/2012 - 11/2007
5Venous Thromboembolism
05/2012 - 01/2008
4Thromboembolism
11/2016 - 01/2009
4Stroke (Strokes)
05/2012 - 01/2008
2Chronic Kidney Failure (Chronic Renal Failure)
03/2015 - 04/2010
2Acute Coronary Syndrome
01/2009 - 09/2007
1Intracranial Hemorrhages (Intracranial Hemorrhage)
01/2017
1Thrombosis (Thrombus)
01/2017
1Epistaxis (Nosebleed)
08/2015
1Erythema
08/2015
1Embolism (Embolus)
02/2012
1Embolic Stroke
10/2010
1Obesity
09/2009
1Body Weight (Weight, Body)
09/2009
1Liver Diseases (Liver Disease)
12/2008
1Gallstones (Gallstone)
11/2007

Drug/Important Bio-Agent (IBA)

21DabigatranFDA Link
01/2019 - 09/2007
8idarucizumabIBA
01/2019 - 07/2015
6AnticoagulantsIBA
01/2017 - 06/2010
5AntithrombinsIBA
05/2012 - 11/2007
2Vitamin KFDA Link
11/2016 - 11/2016
1fibrin fragment D (D-dimer)IBA
01/2017
12- ethyleneimino- 5,6,7,8- tetrahydronaphthoquinone (A 137)IBA
01/2017
1prothrombin fragment 1IBA
01/2017
1Biomarkers (Surrogate Marker)IBA
01/2017
1Pharmaceutical PreparationsIBA
08/2015
1ThrombinFDA Link
03/2015
1prothrombin complex concentrates (PPSB)IBA
06/2010
1Factor VIIa (Activated Factor VII)IBA
06/2010
1CreatinineIBA
04/2010
1Warfarin (Coumadin)FDA LinkGeneric
11/2007
1Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
11/2007
1Transaminases (Aminotransferases)IBA
11/2007

Therapy/Procedure

2Anticoagulation Reversal
11/2016 - 11/2016
2Arthroplasty
02/2012 - 09/2009
1Therapeutics
10/2010
1Hip Replacement Arthroplasty (Total Hip Replacement)
01/2009